OCT 07, 2020 12:00 PM PDT

Drugging the Undruggable Cancer Targets

Sponsored by: ChemPartner
Speaker
  • Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department
    Biography

      Dr. Ming Liu is a Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department. Dr. Liu has more than 25 years of experience in drug discovery and development, with a focus on pre-clinical evaluations of novel therapeutic agents. Dr. Liu obtained his Ph.D. of Molecular Virology from Baylor College of Medicine in Houston, Texas. He received his postdoctoral training at the Dana Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts. He worked for Schering-Plough and Merck Pharmaceuticals for nearly 20 years, focusing on cancer drug discovery and development. Additionally, Dr. Liu is a licensed veterinarian in Taiwan and the United States. He has published 40 peer review articles, 10 patents, and 4 book chapters.


    Abstract

    Cancer is a multifactorial disease, and its genesis and progression are extremely complex. The scope of precision oncology is rapidly expanding to address previously undruggable targets. The term “undruggable” was used to describe proteins that could not be targeted pharmacologically. Many targets in cancer research fall into this category, including KRAS, which has eluded researchers for more than 30 years until recent landmark discoveries of AMG 510, MRTX 849, and BI 1701963. As clinical trials are vigorously advanced, efficacy, safety, resistance, and combination strategies are being carefully evaluated for those drug candidates. In addition to KRAS, there are other challenging targets such as P53, MYC, fusion transcription factors, immuno-suppressors,…etc. The focus of this webinar is to provide an overview of strategies in drugging some perceived undruggable targets, with stories and case studies by scientists who strive to find these medicines and fill unmet patient needs. Experienced in overcoming prior hurdles to find effective antagonists against cancer, as a R&D CRO, ChemPartner has utilized a wide range of integrated approaches such as medicinal chemistry, antibody-drug conjugates, monoclonal antibodies, in vitro biology assays, cell biology, immuno-oncology, pharmacology, and combination therapy to identify and tackle the problems that surround drug development for “undruggable” targets.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    Loading Comments...
    Show Resources